Maharashtra Food and Drugs Administration (FDA) Commissioner Tukaram Mundhe has raised serious concerns regarding the vast disparity between the procurement costs and the Maximum Retail Prices (MRPs) of various medical devices and hospital consumables. A state government survey uncovered markups reaching an astonishing 2,841% on some essential items.
Massive Price Discrepancies Revealed
The comprehensive survey focused on commonly used surgical consumables crucial for inpatient care, including IV infusion sets, syringes, nebulisers, oxygen masks, and catheters. The findings highlighted significant gaps between the prices at which private hospitals acquired these products and what patients were ultimately charged.
- IV Infusion Sets: Reportedly procured for ₹11.05, these were billed to patients at ₹325.
- Catheters: Hospitals procured these for approximately ₹29.41, yet their MRP was ₹310.
Commissioner Mundhe described the findings as revealing an "extraordinary disparity" between trade procurement prices and the printed MRPs, particularly for devices used in inpatient care.
Calls for Regulatory Action and Price Oversight
In response to these findings, Mundhe has formally written to the Department of Pharmaceuticals and the National Pharmaceutical Pricing Authority (NPPA). He advocates for an urgent review of the survey results and the implementation of appropriate regulatory measures. His proposals include:
- Capping trade margins on medical devices.
- Bringing essential medical device categories under structured price monitoring mechanisms.
Mundhe emphasized that many hospital surgical consumables currently fall outside the direct ceiling-price mechanism of the Drugs (Prices Control) Order, 2013. He argues that this regulatory gap allows "unchecked pricing practices" to persist across the supply chain, leading to significant price differences.
A Patient Protection Issue
Framing the issue as critical for consumer and patient protection, Mundhe stated, "This is not merely a pricing issue; it is a patient-protection issue." He pointed out the inherent information asymmetry in healthcare, where patients often lack the means to assess whether the prices charged for medical products are justified. When products procured at low trade prices carry exceptionally high MRPs, the financial burden disproportionately falls on the patient.
NPPA Examination and Broader Implications
The NPPA is reportedly examining whether manufacturers and intermediary supply channels are adding substantial margins before medical devices reach patients. The regulator is comparing company filings and internal price lists with the findings from Maharashtra's survey. Similar concerns have also been raised by drug-control authorities in Punjab, Rajasthan, and Tamil Nadu, suggesting a potential for a nationwide review.
While hospitals acknowledge the need for transparency and patient protection, industry representatives like Dr. Aashish Chaudhry, managing director of Aakash Healthcare, call for a balanced regulatory approach. He noted that hospitals require sufficient profitability to invest in infrastructure, technology, and patient safety, alongside maintaining fair pricing.